Sutro Biopharma Q1 revenue beats analyst expectations

Sutro Biopharma

14/05/2026 21:24

Overview

US oncology platform's Q1 revenue beat analyst expectations

Net loss for Q1 narrowed compared to prior year

Company strengthened cash position with recent capital raise

Outlook

Sutro expects to report initial STRO-004 Phase 1 safety and activity data in mid-2026

Company plans IND submissions for STRO-006 and STRO-227 in 2026

Sutro says cash runway expected into at least Q2 2028

Result Drivers

COLLABORATION REVENUE - Q1 revenue was principally from the Astellas collaboration, including a $10 mln milestone payment for a partnered program entering the clinic

PIPELINE PROGRESS - Co highlighted advancement of key ADC programs, including STRO-004 and dual-payload candidates, as supporting clinical momentum

Company press release: ID:nGNX5b10By

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$14.52 mln
$8.08 mln (11 Analysts)
Q1 Net Income
-$38.48 mln
Q1 Operating Expenses
$44.18 mln
Q1 Operating Income
-$29.66 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sutro Biopharma Inc is $32.00, about 19.2% below its May 13 closing price of $39.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)